Circular RNA (circRNA) is a crucial regulator in multiple human diseases, including osteoporosis (OP). However, the function of numerous circRNAs remains unclear. This study aimed to explore the role and mechanism of circ_0019693 in bone marrow mesenchymal stem cell (BMSC) osteogenic differentiation and osteogenesis-coupled angiogenesis. The expression of circ_0019693, miR-942-5p and purkinje cell protein 4 (PCP4) was measured using quantitative real-time PCR (qPCR) or Western blot. Osteogenic differentiation was monitored according to the protein levels of RUNX family transcription factor 2 (RUNX2), osteopontin (OPN) and osteocalcin (OCN) by Western blot analysis, and the activity of alkaline phosphatase (ALP). Angiogenesis was evaluated by tube formation assay. The targeting relationship between miR-942-5p and circ_0019693 or PCP4 was identified using pull-down, dual-luciferase reporter, and RNA immunoprecipitation assays. Circ_0019693 was downregulated in serum samples and bone tissues from OP patients relative to normal subjects. Circ_0019693 expression was enhanced in the stages of BMSC osteogenic differentiation. Circ_0019693 overexpression enhanced the activity of ALP and the expression of RUNX2, OPN and OCN, and its overexpression also promoted angiogenesis. However, circ_0019693 knockdown played the opposite effects. MiR-942-5p was ensured to be a target of circ_0019693, and miR-942-5p enrichment reversed the effects of circ_0019693. In addition, PCP4 was a target of miR-942-5p, and miR-942-5p inhibitor-promoted BMSC osteogenic differentiation and angiogenesis were partly repressed by PCP4 knockdown. In conclusion, circ_0019693 promotes BMSC osteogenic differentiation osteogenesis-coupled angiogenesis via regulating miR-942-5p-targeted PCP4, thus blocking the development of OP.
Lipid-based nanomedicines (LBNMs) represent a transformative frontier in improving drug bioavailability and achieving spatiotemporally precise delivery of therapeutic agents. However, establishing robust in vitro-in vivo correlation (IVIVC) for LBNMs remains a significant challenge due to the complexity of their interactions with biological systems after administration. Conventional IVIVC approaches, often relying on simplistic in vitro dissolution models, frequently fail to recapitulate dynamic physiological processes, leading to discrepancies between predicted and actual in vivo performance. Recent advancements in understanding protein coronas-mediated phenomena have revolutionized nanomedicines research by unraveling how adsorbed biomolecules at the nanoparticle interface dictate physiological processes such as immune system interplay and biodistribution. This review systematically evaluates the state-of-the-art models for IVIVC of LBNMs and the emerging roles of protein coronas in bridging the gap between in vitro characterization and in vivo behavior, emphasizing the necessity of integrating protein coronas analysis into IVIVC frameworks.